Sonus Pharmaceuticals, Inc. Completes Registered Direct Public Offering
Registered direct public offering for Sonus Pharmaceuticals, Inc. (Nasdaq: SNUS) – $30.6 million.
Sonus Pharmaceuticals later merged with OncoGenex Technologies to become OncoGenex Pharmaceuticals.